WSD-0922-FU

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameWSD-0922-FU
Drug Alias NameWSD0922-FUWSD-0922-FU
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsEpidermal growth factor receptor variant III inhibitors
TargetsEpidermal growth factor receptor erbB1Epidermal growth factor receptor variant III
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesWayshine Biopharm International Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHangzhou Veribo biomedicine Co LtdVision Biological Tech (Hefei) Co LtdMayo Clinic +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A